510(k) reform: Minnesota congressional delegation lines up in opposition of IOM report’s key findings

IOM crushes 510(k)

Lawmakers from the North Star State are falling in line to oppose one of the key findings of the Institute of Medicine’s recent report on the FDA’s 510(k) premarket notification.

Sens Amy Kloubechar (D-Minn.), Al Franken (D-Minn.) and Rep. Erik Paulsen (R-Minn) issued a joint statement saying that they rejected the IOM’s finding that the FDA should scrap the 510(k) program altogether and start anew.

The 22-month, independent IOM review, commissioned in 2009 by the FDA’s Center for Devices & Radiological Health and released last week, is not binding on the agency but is sure to cause a stir in med-tech circles and draw the attention of members of Congress.

“I believe we need targeted reforms to the 510(k) process to ensure that our companies in the medical device industry can continue to create jobs, develop innovative products, and maintain patient safety,” Kloubechar said in a prepared release. “Scrapping the 510(k) process entirely isn’t what our businesses want and could limit access to life-saving products.”

Kloubechar’s Senatorial counterpart Al Franken added that “calling for the elimination of the 510(k) process could be very harmful to innovation. The report’s recommendations would impose new burdens on the medical device industry, without a clear path to a more effective process. And in the meantime, it would leave Minnesota companies with great uncertainty, and patients without new lifesaving devices.”

Both Franken and Kloubechar have been active voices in the senate supporting the device industry, along with Rep. Erik Paulsen, who heads the Medical Technology Caucus in the House of Representatives. He called the IOM report’s recommendation to scrap the program a “step in the wrong direction.”

“The medical technology industry is already facing unprecedented challenges – a job-stifling innovation tax and an increasingly out-of-touch FDA – and eliminating the 510(k) process would give Europe another leg up in competing for these made-in-America technologies,” Paulsen said. “What the medical devices manufacturers need is consistency in the approval process, not more uncertainty. Instead of replacing 510(k), I intend to work with innovators, physicians, and other stakeholders to streamline the device clearance process at the FDA.”

Sen. Scott Brown (R-Mass.) told MassDevice via email that he was “reviewing the IOM recommendations in the context of MDUFMA reauthorization, with a critical eye on how these recommendations could further add to the uncertainty in the FDA regulatory process for the medical device industry.”

“I will continue to closely follow and monitor these discussions, and listen to the device industry in Massachusetts about the proposed changes to the 510k process,” Brown wrote.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Comments

  1. FDA Regulatory Specialist for Industry says

    I believe the response from the Senators is overly dramatic and misses the value of the IOM Report offers. The 510k/PMA models are antiquated and they need more than a “patch”, they need to be redesigned and based on a risk model and not a predicate model where the predicate can be as much as 35 years old. Continuing this patch work or mosaic approach is not helpful to the patients, physicians, or the medical device industry which includes the FDA. Allowing the current predicate based model to continue prevents innovation and increases the uncertainty for both industry and the FDA reviewers. When a new device is developed, investors want a 510k route regardless of the risk. But if a device does not have a predicate than regardless of the risk, the FDA must view the device in the highest risk until the manufacturer can prove it is not. This is a waste of time and resources both for Industry and the FDA. The FDA has the “de novo” approach but this is a cumbersome, ineffective make shift process that adds no value but creates an enormous amount of work for industry and the FDA. It adds complete uncertainty to regulatory process which investors find unacceptable and will walk away from promising technology because of the regulatory uncertainty.
    The PMA and 510k model approach is antiquated and the EU got it right. Adapt a risk based approach. This is not going to be hard, almost all companies already have EU clearance, they already know how to implement those regulations, and the classification is predictable.
    The majority of complaints regarding FDA reviews are a lack of consistent, predictable, and transparent market applications, regardless if the product is a 510k or PMA. Obtaining classification is only an entry step that has been turned into a road block. The real work that needs to be done regardless of the classification is the training and education of the reviewer. Until we require and fund the FDA to implement a formal Reviewer Training Program that includes a minimum level of expertise, requires continuing education standards, and retention packages, changing the model will not impact consistent, predictable, and transparent reviews of market applications.

  2. says

    I simply want to mention I am just new to weblog and seriously loved you’re blog. Probably I’m going to bookmark your site . You absolutely come with great articles and reviews. Thanks a bunch for revealing your webpage.

Trackbacks

  1. Nice article

    Apakah anda membutuhkan obat herbal de Nature Indonesia silahkan dapat hubungi customer service kita secara langsung melalui SMS ataupun Telepon. Kami selalu online 24 jam utk melayani pembelian obat herbal de Nature.

  2. Thank you

    Apakah agan wati membutuhkan obat herbal de Nature Indonesia silahkan bisa hubungi customer service kami secara langsung via SMS ataupun Telepon. Kami selalu online 24 jam untuk melayani pemesanan produk herbal de Nature.

Leave a Reply